N06AB03 fluoxetine
NERVOUS SYSTEM ›PSYCHOANALEPTICS ›ANTIDEPRESSANTS ›Selective serotonin reuptake inhibitors
健保收載品項 TFDA 在效許可證 18 FDA 已核准 健保給付條款 1
台灣藥品與外觀
健保收載品名:"中國化學"憂適停膠囊20毫克(富魯歐西汀)、"信東" 信樂膠囊20毫克、"優良"優喜膠囊20毫克(富魯歐西汀)、"嘉林"伏憂膠囊20毫克、"大豐" 免憂膠囊20公絲(富魯歐西汀)、"威勝"克憂膠囊10毫克、"威勝"克憂膠囊20毫克(富魯歐西汀)、"永信"伏憂寧膠囊10毫克 F、"永信"伏憂寧膠囊20毫克、"生達" 伏鬱微粒膠囊20公絲(富魯歐西汀)、"生達"伏鬱微粒膠囊10公絲、〝順生〞喜無憂膠囊20公絲(富魯歐西汀)、即克憂膠囊20公絲、喜無愛膠囊10公絲(富魯歐西汀)、媚姿雅®膠囊20毫克、安保福憂停膠囊20公絲
資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 抑鬱症、暴食症、強迫症。
- 抗憂鬱劑。
- 抗鬱劑。
美國 FDA 適應症(英文原文對照)
1 INDICATIONS AND USAGE Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years. ( 1.1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adults and pediatric patients aged 7 to 17 years. ( 1.2 ) Acute and maintenance treatment of Bulimia Nervosa in adult patients. ( 1.3 ) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients. ( 1.4 ) 1.1 Major Depressive Disorder Fluoxetine tablets are indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to 18 years [see Clinical Studies (14.1) ] . The usefulness of the drug in adult and pediatric patients receiving fluoxetine tablets for extended periods should periodically be re-evaluated [see Dosage and Administration (2.1) ] . 1.2 Obsessive Compulsive Disorder Fluoxetine tablets are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . The effectiveness of fluoxetine tablets in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.2) ] . 1.3 Bulimia Nervosa Fluoxetine tablets are indicated for the acute and maintenance treatment of binge-eating and vomiting behaviors in adult patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . The physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.3) ] . 1.4 Panic Disorder Fluoxetine tablets are indicated for the acute treatment of Panic Disorder, with or without agoraphobia, in adult patients [see Clinical Studies (14.4) ] . The effectiveness of fluoxetine tablets in long-term use, i.e., for more than 12 weeks, has not been established in placebo-controlled trials. Therefore, the physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.4) ] .
資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。
健保給付規定
上層 ATC 繼承條款
繼承自 ATC N06AB
§ 1.2.1 戒菸治療藥品 — narrative parent
神經系統藥物 › 精神治療劑
選擇性血清促進素再吸收抑制劑(SSRI)、血清促進素及正腎上腺素再吸收抑制劑(SNRI)及其他抗憂鬱劑(fluvoxamine maleate、fluoxetine、paroxetine、sertraline、venlafaxine、milnacipran、mirtazapine、citalopram、escitalopram、duloxetine、agomelatine、vortioxetine等製劑):(88/12/1、89/10/1、91/5/1、92/6/1、93/5/1、94/2/1、94/12/1、99/10/1、101/7/1、107/3/1) 使用時病歷上應詳細註明診斷依據及使用理由。
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。